Approach to Metastatic Disease

Opinion
Video

Panelists discuss how the approach to metastatic disease focuses on systemic therapy, as cancer has spread beyond its primary site. Treatment typically combines targeted therapy, immunotherapy, chemotherapy, and/or hormonal therapy based on cancer type and molecular profile. Goals shift toward extending survival, controlling symptoms, and maintaining quality of life rather than cure. Regular monitoring of treatment response and adverse effects guides ongoing care decisions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content
No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
April 17th 2025
Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber, MD, MPH
November 15th 2017
Podcast

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC

Kristie L. Kahl
April 22nd 2024
Article

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Peter Schmid, MD
April 7th 2017
Podcast

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC

Ariana Pelosci
March 22nd 2024
Article

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

Russ Conroy
February 13th 2024
Article

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.